Tango Therapeutics, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Blueprint Medicines Corp (BPMC)
CIK: 0001597264
Period of Report: 2021-12-08

Reporting Person: Tango Therapeutics, Inc. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	A	3400	—	Acquired	3400	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Stock Option (Right to Buy)	$98.72	A	7000	Acquired	2031-12-08	Common Stock (7000)	Direct

Footnotes

F1: The reported transaction involved the Reporting Person's receipt of a grant of 3,400 restricted stock units in accordance with the Issuer's non-employee director compensation policy.

F2: This option vests with respect to 1/36th of the shares underlying the option on January 8, 2022 and as to an additional 1/36th of the shares underlying the option each month thereafter.